Brought to you by 
Fisher Scientific buys Apogent for $3.7bn
03 Aug 2004
Executive Summary
Continuing on its buying spree, life sciences company Fisher Scientific has paid $3.7bn ($2.7bn in stock plus the assumption of debt) to buy Apogent Technologies (develops laboratory and life science research equipment). The deal values Apogent at $30.15 a share, a slight premium to its pre-announcement market average.
Deal Industry
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Fisher Scientific buys Apogent for $3.7bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice